Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017203304) PYRAZINE DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH CELL CYCLE DYSREGULATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/203304 International Application No.: PCT/GR2017/000027
Publication Date: 30.11.2017 International Filing Date: 23.05.2017
IPC:
A61K 31/497 (2006.01) ,A61P 35/00 (2006.01) ,A61P 43/00 (2006.01) ,A61P 31/12 (2006.01) ,A61P 3/00 (2006.01) ,A61P 9/10 (2006.01) ,A61P 9/00 (2006.01) ,A61P 7/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
497
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
Applicants:
UNIVERSITY OF PATRAS [GR/GR]; GR
TARAVIRAS, Stavros [GR/GR]; GR
LYGEROY, Zoi [GR/GR]; GR
KARANTZELIS, Nikolaos [GR/GR]; GR
Inventors:
UNIVERSITY OF PATRAS; GR
TARAVIRAS, Stavros; GR
Priority Data:
2016010028123.05.2016GR
Title (EN) PYRAZINE DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH CELL CYCLE DYSREGULATION
(FR) DÉRIVÉS DE PYRAZINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES ASSOCIÉES À UN DÉRÈGLEMENT DU CYCLE CELLULAIRE
Abstract:
(EN) The present invention provides pyrazine derivatives according to formula (I), their enantiomers, stereoisomers, salts and hydrites thereof, for use in the treatment of diseases associated with cell cycle dysregulation, wherein R1, R2, k, X, R3, R4, R6, R7, m, Y, R11, R5, n, R8, R9 and R10 are as defined in the claims. Also provided for use in the treatment of said diseases are pharmaceutical compositions comprising the compounds of the present invention in combination with one or more pharmaceutically acceptable carriers, solvents or excipients. Said diseases that are associated with cell cycle dysregulation are selected, among others, from a group comprising cancer, hamartoma, inflammatory disease, haematological disorder, viral disease with the potential of inducing carcinogenesis, metabolic disorder, progeroid syndrome, atherosclerosis, and vasculoproliferative disorder. (I)
(FR) La présente invention porte sur des dérivés de pyrazine selon la formule (I), sur leurs énantiomères, sur leurs stéréoisomères, sur des sels et sur des hybrides de ces derniers, destinés à être utilisés dans le traitement de maladies associées à un dérèglement du cycle cellulaire, où R1, R2, k, X, R3, R4, R6, R7, m, Y, R11, R5, n, R8, R9 et R10 sont tels que définis dans les revendications. La présente invention porte également sur des compositions pharmaceutiques destinées à être utilisées dans le traitement desdites maladies et comprenant les composés de la présente invention en combinaison avec un ou plusieurs véhicules, solvants ou excipients pharmaceutiquement acceptables. Lesdites maladies qui sont associées à un dérèglement du cycle cellulaire sont sélectionnées, entre autres, dans un groupe comprenant le cancer, l'hamartome, une maladie inflammatoire, un trouble hématologique, une maladie virale ayant le potentiel d'induire la carcinogenèse, un trouble métabolique, le syndrome de progéroïde, l'athérosclérose et un trouble vasculoprolifératif.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)